Blood Journals Portfolio
Jun 21, 2026, 16:12
Cost Savings and Reduced Factor Consumption With Efanesoctocog Alfa – Blood Journals Portfolio
Blood Journals Portfolio shared a post on X about a recent article by Janice M. Staber et al, adding:
”The high-sustained FVIII therapy efanesoctocog alfa resulted in 3 to 5.5 times lower consumption and may save USD 38 947 to USD 81 000 per surgery.
Read the full study in Blood VTH.”
Title: Cost comparison of efanesoctocog alfa vs conventional factor VIII therapies for major surgeries in patients with severe hemophilia A
Authors: Janice M. Staber, Alix Arnaud, Ion Agirrezabal, Duygu Bozkaya, Lane Anson, Andrew Wilson, Nana Kragh, Doris Quon, Allison P. Wheeler
Stay updated on all scientific advances with Hemostasis Today.
-
Sep 21, 2026, 15:56Anita Zaidi: Why Only 2% of Health Research and Development Goes to Women’s Conditions
-
Sep 21, 2026, 15:49Omid Khalafi: Gating Strategy and How Do We Decide Which Cells to Analyze
-
Sep 21, 2026, 15:44Levacetylleucine: A New Therapeutic Approach to Ataxia Telangiectasia
-
Sep 21, 2026, 15:40Andreas Tridimas: The Diagnostic Traps of Lipaemic Blood – Why a Normal Amylase Can Mislead You
-
Sep 21, 2026, 15:33Arsene Mekinian: Exploring Cardiac Involvement in Behçet’s Disease
-
Sep 21, 2026, 15:23Anis Mahjoubi: MRI Findings of Krukenberg Tumors
-
Sep 21, 2026, 15:08Fikreab Tesfaye Tefera: 10 Practical Take-Home Points for Diagnosing Iron Deficiency Anemia
-
Sep 21, 2026, 14:10Aswin K Mohan: Lessons from TRANSCON 2026 – Building Resilient Blood Supply Systems Before Crisis Hits
-
Sep 21, 2026, 14:00Vincent Lu: Beyond PT and aPTT – How Hemostasis Evolves Across a Lifetime